[의학신문·일간보사=정민준 기자]On the 26th, the Ministry of Food and Drug Safety (Director Kang-lip Kim) approved a phase 2 clinical trial for the domestically developed Corona 19 treatment’Rineekju’.
 |
‘Rineekju’, which was approved this time, is currently being used for the treatment of liver function improvement by subcutaneous or intramuscular administration, and this clinical trial was applied by changing it to intravenous intravenous administration.
This clinical trial is a phase 2 clinical trial to evaluate the efficacy and safety of patients with COVID-19.
Currently, 8 vaccines and 14 therapeutics (12 components) are currently being developed with approval for clinical trials related to Corona 19 in Korea, of which one drug has been approved in Korea.
‘Reinekju’ has confirmed the antiviral effect of reducing the amount of virus and reducing the cytopathic effect caused by viral infection through a non-clinical test.
In Russia, a paper was published confirming that the clinical symptoms were improved compared to the control group when administering a hydrolyzate to Corona 19 patients.
An official from the Ministry of Food and Drug Safety said, “In the future, considering the high public interest in the development of COVID-19 treatment and vaccine, we will quickly deliver information on the status of clinical trials of the developed product.” We will do our best to support the development so that our people can receive treatment opportunities.”
Reporter Jeong Min-joon [email protected]
<저작권자 © 의학신문, 무단 전재 및 재배포 금지>